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ABSTRACT
Background and Objectives: It was reported that atorvastatin co-administered with clopidogrel for 8 months did not affect 
the anti-platelet potency of clopidogrel in Korean patients with acute coronary syndrome, but not in patients with stable an-
gina. We investigated whether co-administration of statins with clopidogrel affected the anti-platelet efficacy of clopidogrel 
in Korean patients with stable angina. Subjects and Methods: This was a randomized, open-label and two-period crossover 
design study conducted at two centers. Two hundreds thirty three patients with stable angina scheduled for coronary stent-
ing were randomized into two groups. In Group A, 119 patients first received atorvastatin (10 mg) followed by fluvastatin (80 
mg) for 12 weeks per treatment. In Group B, 114 patients received the same treatments in reverse order. Results: Baseline 
adenosine diphosphate (ADP, 10 μmol/L)-induced platelet aggregation was 54.4±9.1% in Group A and 53.8±9.0% in Group 
B (p=0.44), and significant differences were noted after each treatment period (p<0.001). Inhibition of platelet aggregation 
was similar between Group A and Group B at 24 hours following clopidogrel loading (29.2±11.0% vs. 30.4±12.7%; p=0.42). 
The two treatment least square means of 12-week ADP (10 mol/L)-induced platelet aggregation [29.50±0.79 {standard error 
(SE)}% on the atorvastatin treatment group vs. 28.16±0.70 (SE)% in the fluvastatin treatment group] in a 2×2 cross-over study 
were not significantly different (p=0.204). Conclusion: Statin and clopidogrel co-administration for 12 weeks is not associ-
ated with attenuated anti-platelet activity of clopidogrel in Korean patients with stable angina after coronary stenting, in 
support of the findings of similar studies conducted in Caucasian populations. (Korean Circ J 2011;41:28-33)
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Introduction
Several large, randomized clinical trials and their meta-an-
alyses have demonstrated the benefits of clopidogrel as an 
alternative to aspirin in patients at high risk for cardiovascu-
lar events.
1-5) Clopidogrel decreases the incidence of coronary 
artery stent thrombosis and has been approved for the reduc-
tion of myocardial infarction incidence, atherosclerotic cere-
bral infarction and vascular diseases.
6)7) Likewise, 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (statins) 
were found to reduce the risks of myocardial infarction, st-
roke and cardiovascular-related death in randomized trials 
and their meta-analyses.
8-10) Therefore, clopidogrel and statins 
are being frequently co-administered in patients with coronary 
artery stents. 
Clopidogrel, an inactive thienopyridine prodrug in vitro, is 
activated in vivo by cytochrome P450 enzyme (CYP3A4) fol-
lowing oral administration.
11-13) This active metabolite binds 
selectively and irreversibly to the platelet purinergic P2Y12 re-
ceptor, thereby inhibits adenosine diphosphate (ADP)-induc-
ed platelet aggregation. Some statins (e.g., atorvastatin, simv-
astatin, lovastatin) are predominantly metabolized by hepatic 
CYP3A4. Therefore, there has been controversies regarding 
possible drug interactions via this metabolic pathway after re-Goeng Bae Kim, et al.   29
ports revealed that the anti-platelet activity of clopidogrel could 
be attenuated by lipophilic statins in patients undergoing co-
ronary artery stenting.
14-16) However, the data from several cli-
nical follow-up studies on major adverse events indicate that 
peri-procedural co-administration of statins with clopido-
grel does not worsen the clinical progress of such patients.
17)18) 
Although severe drug-drug interactions between statins and 
clopidogrel have not been reported in recent ex vivo studies,
19-22) 
the follow-up durations of these studies (maximal duration=5 
weeks) cannot be considered sufficient to reflect the long-
term clinical outcomes of such combination therapy. Fur-
thermore, concomitant prescription of statins with clopido-
grel is common worldwide in patients who undergo percu-
taneous coronary intervention, but there have been few re-
ports on the impact of co-administering statins and clopido-
grel on the anti-platelet activity of clopidogrel in Asians. Re-
cently, Hong et al.
23) demonstrated no significant differences 
in anti-platelet potency of clopidogrel when it was co-admini-
stered with 10 mg or 40 mg of atorvastatin for eight months 
in patients with acute coronary syndrome.
23)
The aim of this study was to evaluate consecutively whe-
ther the anti-platelet efficacy of clopidogrel would be similar-
ly maintained over a 12-week period, when it was adminis-
tered concomitantly with statins with different metabolic pa-
thways in Korean patients with stable angina after coronary st-
enting.
Subjects and Methods 
Patients
This was a randomized, open-label, two-sequence, two-pe-
riod crossover design study conducted at two centers. The 
hospital institutional review board reviewed and approved 
the study protocol. The study was conducted in accordance 
with the principles set forth in the Guideline for Good Clini-
cal Practice and the Declaration of Helsinki and its amend-
ments.
24)
Patients newly diagnosed with stable angina scheduled for 
coronary stenting, and who had never received treatment for 
hypercholesterolemia {low density lipoprotein-cholesterol 
(LDL-C) ≥100 mg/dL} were recruited. One month prior to 
study entry, no patients received statin therapy. Eligible pa-
tients were informed of the nature of the study and gave writ-
ten informed consent.
Exclusion criteria
Patients with acute coronary syndrome, active bleeding, 
bleeding diathesis, malignancies, oral anticoagulation therapy 
using a coumadin derivative, recent treatment (<14 days prior) 
using a glycoprotein IIb/IIIa antagonist or a platelet count 
<100×10
9/L were excluded. In addition, patients taking known 
CYP3A4 inducers or inhibitors were excluded, unless they 
were taking one of the drugs included in Table 1. 
Screening, randomization and treatment
Enrolled patients were randomized with sequentially num-
bered, opaque sealed envelops containing sheets containing 
details of the assigned treatment. Of 260 enrolled patients, 233 
were randomly assigned to one of two treatment sequences 
using permuted block randomization in blocks of six. Group 
A was comprised of 119 patients who received atorvastatin 
first just after coronary stenting, followed by fluvastatin (Le-
scol XL
R; Norvatis Pharma AG). In Group B, 114 patients first 
received fluvastatin just after coronary stenting followed by 
Table 1. Demographic and clinical characteristics of the intention-to-treat population
Characteristic Group A (n=119) Group B (n=114) p* Total (n=233)
Age (year) 57.9±11.3 60.1±10.8 0.741 59.2±11.6
Female gender 42 (35.3) 39 (34.2) 0.801 081 (34.8)
BMI (kg/m
2) 23.7±2.60 22.9±3.10 0.798 22.7±5.60
Risk factors
Current smoking 14 (11.6) 12 (10.5) 0.821 026 (11.2)
Hypertension 75 (63.0) 72 (63.2) 0.885 147 (63.1)
Diabetes mellitus 39 (32.8) 35 (30.7) 0.761 074 (31.8)
Medication
CCB 65 (54.6) 66 (57.8) 0.843 131 (56.2)
β-blocker 74 (62.2) 76 (66.7) 0.635 150 (64.4)
ACE inhibitor 59 (49.6) 56 (49.1) 0.623 115 (49.4)
ARB 48 (40.3) 43 (37.7) 0.493 091 (39.1)
Nitrates 31 (26.1) 29 (25.4) 0.794 060 (25.8)
Diuretics 17 (14.3) 13 (11.4) 0.834 030 (12.9)
The data are expressed as the mean±SD or number (percentage). *Comparison between Group A and Group B. BMI: body mass index, CCB: 
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atorvastatin. All drugs were administered once daily in the 
morning at a dose of 10 mg for atorvastatin and 80 mg for 
fluvastatin for each 12 week per treatment period. A 4-week 
washout interval separated the treatment periods, during wh-
ich pravastatin, which is not metabolized mainly via the CYP 
pathway in the liver, was given once daily. The comparative ef-
ficacy of the available statins on lipids and lipoproteins show-
ed that the potency of 10-mg atorvastatin is similar to that of 
80-mg fluvastatin.
25) All patients received 100-mg aspirin and 
a 300-mg loading dose of clopidogrel before coronary stent-
ing, and daily doses of 75-mg clopidogrel and 100-mg aspirin 
after coronary stenting during the study. Compliance with the 
treatments was monitored through patient diaries and period-
ic telephonic follow-ups between assessments. Patients were 
instructed to follow the National Cholesterol Education Pro-
gramme Step I (or stricter) diet. 
Laboratory tests
Blood samples for platelet activity were drawn 1 hour be-
fore (baseline) and 24 hours after the loading dose of clopido-
grel, as well as after each treatment period at weeks 12 and 24. 
A blood sample was taken from the forearm vein and collect-
ed in a 3.8% sodium citrate tube. Platelet aggregation was as-
sessed within 2 hours of blood sampling. Ex vivo platelet ag-
gregation was measured using a two-channel whole blood ag-
gregometre (Chrono-log Corp., Havertown, PA, USA). Plate-
let-rich plasma was obtained as a supernatant after centrifug-
ation of the citrated blood at 1,000 rpm for 10 minutes. The fi-
nal platelet count was adjusted to 2×10
8/mL with autologous 
plasma. Platelet-poor plasma was obtained by a second cen-
trifugation of the blood at 3,500 rpm for 10 minutes. The 
maximal light transmission curve was assessed for 5 minutes 
after adding 10 μmol/L ADP as a marker for platelet aggrega-
tion. The platelet-poor plasma was used as the baseline reference.
All patients were required to fast for 12 hours before blood 
sampling for serum lipid parameter concentrations. Serum 
LDL-C, total cholesterol (TC), triglyceride (TG) and high den-
sity lipoprotein cholesterol (HDL-C) concentrations were de-
termined at baseline, weeks 12 and 24. The LDL-C concen-
trations were calculated by using the Friedewald formula.
30) 
TC and TG concentrations were measured by calorimetric 
enzyme assay using a Hitachi 747-200 automatic analyzer. 
HDL-C was measured after precipitation by a calorimetric en-
zyme assay. Our laboratory has been certified by the Korean 
Association of Quality Assurance for Clinical Laboratories, 
Seoul, Korea.
Statistical analysis
The analysis was performed according to the intention-to-
treatment (ITT) principle, defined as patients who received 
≥1 dose of a study drug and had data available from ≥1 fol-
low-up assessment in each of the study period. Comparisons 
of lipid concentrations were based on all randomized pa-
tients who had taken at least one dose of atorvastatin or flu-
vastatin. Continuous demographic parameters and study data 
were expressed as the mean±SD, and comparisons between 
the groups were analyzed by independent t-tests. Power analy-
sis was performed with G Power Version 3.0.
26) All the tests 
were two-tailed. For analysis of the Student’s t-test, the effec-
tive total sample size to give a power level of 0.95 (α=0.05, esti-
mated effect size=0.5) was 210. Categorical variables in the 
baseline characteristics were analyzed using the chi-square test. 
We used the paired t-test to analyze the results within each gr-
oup. We considered the results of the two-sided tests signifi-
cant if the p was less than 0.05. All statistical analyzes were per-
formed using SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL, 
USA).
Statistical analyzes for the comparison of least squares means 
with standard error (SE) for 12-week ADP (10 mol/L)-induc-
ed platelet aggregation (atorvastatin group vs. fluvastatin gr-
oup) in a 2×2 crossover design were estimated from the mo-
del that included treatment, period, and carryover effect using 
NCSS software for Windows (NCSS, Kaysville, Utah, USA; 
NCSS version 2007) according to the methodology describ-
ed by Chow and Liu.
31)32) 
Results
Fig. 1 summarizes the study patient flow. Of the 233 enroll-
ed patients, 119 patients were randomized to Group A and 114 
patients to Group B. A total of 22 patients were withdrawn 
from the study, 12 from Group A and 10 from Group B due to 
consent withdrawal, non-compliance and other factors. The de-
mographic and clinical characteristics of 223 enrolled patients 
included in the ITT population are summarized in Table 1. 
The baseline values of ADP-induced platelet aggregation 
were similar between the groups: 54.4±9.1% for Group A and 
53.8±9.0% for Group B {95% confidence interval (CI) of dif-
ferences=-2.13, 3.02; p=0.44}. These values showed significant 
differences when compared with the results after each treat-
ment period (p<0.001). As shown in Fig. 2, platelet aggrega-
tion was similarly inhibited in Groups A and B: 29.2±11.0% 
vs. 30.4±12.7% (95% CI of differences=-5.12, 1.81; p=0.42) 24 
hours following clopidogrel loading (day 1), 30.8±11.8% vs. 
28.1±10.3% (95% CI of differences=-1.16, 5.49; p=0.08) after 
Period 1 (week 12), and 27.0±11.6% vs. 28.2±10.9% (95% 
CI of differences=-2.98, 3.22; p=0.45) after Period 2 (week 
24). Co-administration of clopidogrel with atorvastatin or flu-
vastatin inhibited platelet activity to the same extent as with 
clopidogrel alone within each group: Day 1 vs. week 12 (p= 
0.31), day 1 vs. week 24 (p=0.61) and week 12 vs. week 24 (p= 
0.12) in Group A. Day 1 vs. week 12 (p=0.23), day 1 vs. week 
24 (p=0.19) and week 12 vs. week 24 (p=0.82) in Group B. 
The two treatment least square means of the 12-week ADP Goeng Bae Kim, et al.   31
(10 mol/L)- induced platelet aggregation {29.50±0.79 (SE)% 
on the atorvastatin treatment group vs. 28.16±0.70 (SE)% in 
the fluvastatin treatment group} in a 2×2 cross-over study were 
not significantly different (p=0.204) (Fig. 3).
The baseline values of lipid parameters were not signifi-
cantly different between the groups, and changes from the 
baseline values were consistent in both groups (Table 2). Liver 
enzyme levels were not elevated ≥3 times the upper limit of 
the normal, nor were the creatinine kinase levels elevated ≥10 
times the upper limit of the normal. Further, no rhabdomyoly-
sis was reported.
Discussion
In this study, co-administration of clopidogrel with atorv-
astatin or fluvastatin inhibited platelet activity to the same 
extent as with clopidogrel alone within each group.
The results of this study, which had a longer follow-up pe-
riod than previous ex vivo studies, suggest that co-adminis-
tration of a CYP3A4-metabolized statin such as atorvastatin 
(metabolized by CYP3A4) or non-CYP3A4-metabolized st-
atin such as fluvastatin (metabolized by CYP2C9) with clopi-
dogrel does not significantly affect the anti-platelet efficacy 
of clopidogrel in Korean patients with symptomatic coronary 
artery disease treated by coronary stenting. Overall, the treat-
ments were well tolerated and no adverse effects were observ-
ed. To our knowledge, this is the longest randomized study in-
vestigating the impact of statins on ex vivo anti-platelet effect 
of clopidogrel. 
A number of concerns were raised regarding the possibili-
ty of specific deleterious interactions between clopidogrel and 
statins when studies provided controversial results that short-
Screened (n=260)
Randomized (n=233)
Atorvastatin (n=119)
Completed atorvastatin
treatment (n=111)
Crossover to fluvastatin
Withdrawn (n=4)
-noncompliance (3)
-consent withdrawn (1)
Withdrawn (n=4)
-noncompliance (3)
-other (1)
Withdrawn (n=8)
-consent withdrawn (3)
-noncompliance (4)
-other (1)
Withdrawn (n=6)
-consent withdrawn (2)
-noncompliance (2)
-other (2)
Completed fluvastatin
treatment (n=107)
Group A:
Atorvastatin-Fluvastatin
Group B:
Fluvastatin-Atorvastatin
Fluvastatin (n=114)
Completed fluvastatin
treatment (n=108)
Crossover to atorvastatin
Completed atorvastatin
treatment (n=104)
Not randomized (n=27)
Fig. 1. The study protocol.
Fig. 2. Inter-individual time dependency of adenosine diphosphate 
(ADP, 10 μmol/L)-induced platelet aggregation from the baseline 
(day 0), through 300-mg clopidogrel loading (day 1), to clopidogrel 
co-administration with atorvastatin or fluvastatin (weeks 12 and 24) 
in the intention-to-treat population. The bars and whiskers represent 
the mean and standard deviation, respectively.
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term therapy with clopidogrel in conjunction with atorvas-
tatin could attenuate the anti-platelet efficacy of clopidogrel, 
suggesting that the co-administration of CYP3A4-metaboliz-
ed statins with clopidogrel may competitively inhibit meta-
bolic activation of clopidogrel in the liver.
14-16) However, Sere-
bruany et al.
20) showed that atorvastatin did not affect platelet 
biomarkers after clopidogrel administration, compared with 
other statins or no statin, within 24 hours in patients under-
going coronary stenting. Mitsios et al.
19) showed that the th-
erapeutic efficacy of clopidogrel in patients with acute coro-
nary syndrome was not significantly affected by concomitant 
administration of atorvastatin for 5 weeks, and clopidogrel 
did not affect the therapeutic efficacy of atorvastatin. Mukher-
jee et al.
21) reported that there was no significant difference in 
the clinical benefit between a CYP3A4-metabolized statin 
and a non-CYP3A4-metabolized statin when used in con-
junction with clopidogrel. The present study has contributed 
to the growing body of evidence that drug-drug interaction 
between clopidogrel and statins has no clinical relevance in 
patients with cardiovascular disease treated with clopidogrel 
and a standard statin-dosing regimen.
This study has several limitations. First, its open-label, un-
blinded design limits its generalizability beyond the study 
groups. However, randomized assignment of patients and the 
crossover design of this study could mitigate bias. The cross-
over design was considered feasible if a sufficiently long wash-
out period could be included between the treatments. Second, 
we investigated only a single platelet function marker. Neu-
bauer et al.
16) demonstrated that the impact of statins on clopi-
dogrel’s inhibitory effect on platelet function was much less im-
pressive when maximal concentrations of ADP (100 mol/L) 
are used. They speculated that very high concentrations of 
ADP stimulated platelets via additional, unspecific receptor 
sites. Furthermore, low concentrations of ADP (1 mol/L) ex-
erted only minor platelet stimulation, but significant results 
were seen when a moderate concentration of ADP (10 mol/
L) was used for platelet stimulation.
16) Therefore, we chose this 
concentration of ADP (10 mol/L) as our stimulation dose 
for platelet aggregometry. Finally, no in vivo investigations 
had been performed, and the study included only the usual 
basal dosage of atorvastatin. However, data from a post hoc 
analysis of the Clopidogrel for Reduction of Events during 
Observation trial showed no adverse effect on the 28-day or 
1-year composite clinical end points with clopidogrel and st-
atin co-administration.
17) Similarly, the prospective Maximal 
Individual Therapy of Acute myocardial infarction PLUS re-
gistry demonstrated that there was no significant difference 
between atorvastatin therapy and other statin therapies in the 
clinical outcomes of patients receiving clopidogrel over a fol-
low-up period of 14 months.
18) Further studies on clopido-
grel-dependent platelet inhibition with dosing increments of 
statins may be needed. Polymorphisms of CYP2C19 could 
have affected clopidogrel resistance in this study.
27)28) Howev-
er, the incidence of clopidogrel non-responders is known to 
be less than 10%.
29) 
In conclusion, the anti-platelet activity of clopidogrel was 
maintained when co-administered with a statin for 12 weeks 
in Korean patients with coronary stents. The results support 
the long-term clinical benefit of a CYP3A4-metabolized and 
non-CYP3A4-metabolized statins administered concomi-
tantly with clopidogrel.
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